Pivotal ALPHA Phase III trial results will show benefit of danicopan, Alexion's first-in-
class Factor D inhibitor, in improving clinically significant extravascular haemolysis
while allowing patients with PNH to remain on standard of care treatment
Calquence data will reinforce role as a preferred treatment option for chronic
lymphocytic leukaemia and mantle cell lymphoma
Interim clinical data will show promise of AZD0486, a novel T-cell engager for patients
with relapsed or refractory follicular lymphoma
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
